A. Second, his in-depth
knowledge in Parkinson's disease and stroke will benefit the clinical
development of ALTROPANE(R) and Inosine, as well as the pre -clinical
development of our Parkinson's therapeutic, O-1369," said Mark Pykett,
President and Chief Operating Officer of BLSI.D. Bianchine. ALTROPANE(R) is in Phase III
for the diagnosis of Parkinsonian Syndromes (PS) and Phase II for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) .
Boston Life Sciences assumes no obligations to update the information
in this press release.

"The
Future of Public Health -- What Will It Take to Keep Americans Healthy and
Safe?" will be held from 3 p.edu/symposium
or contact John M. Earl Fox, MD, MPH
Johns Hopkins School of Public Health

Jeffrey P.

it work

Boston Life Sciences Inc. Appoints Joseph R. Bianchine M.D. Ph.D. F.A.C.P. F.A.C.C.P. to Scientific Advisory Board

, F.P.C. Bianchine has authored over 300 scientific articles and book
chapters in the area of clinical pharmacology and founded the
Parkinson 's Disease Research Institute at Texas Tech."

About Boston Life Sciences

Boston Life Sciences , Inc. on Tuesday, May 10, in USP's
Griffith Hall, located at 600 South 43rd Street, Philadelphia , Pa. The event is free and open to the public.

University of the Sciences in Philadelphia is a private, coeducational
institution founded in 1821 as Philadelphia College of Pharmacy, the first
college of pharmacy in North America.

people life

Bianchine
is also currently a Fellow of the American College of Physicians and
the American College of Clinical Pharmacology, a Diplomat of the
American Board of Clinical Pharmacology and a member of the Editorial
Board for the Journal of Clinical Pharmacology , a position he has held
for the past 23 years. The
Company's research and pre-clinical CNS programs include Inosine for
the treatment of stroke and O-1369 for the treatment of Parkinson's
disease . Koplan, MD, MPH
Emory University

James S.

work university

Business Editors/Medical Editors

BOSTON----Boston Life Sciences, Inc.P. Bianchine strengthens our organization in two ways. Bianchine 's experience spans both industry
and academia: he has held senior positions at Pharmacia + Upjohn ,
Farmitalia-Carlo Erba and Hoffman LaRoche, as well as faculty
positions at Ohio State University College of Medicine, Texas Tech
University (Lubbock) and Johns Hopkins University College of Medicine .
Dr. BLSI's current research collaborations include Harvard
Medical School, Children's Hospital of Boston and the University of
Massachusetts-Worcester.

m.martin@usip.edu. Comprising four colleges across a broad
range of majors, USP specializes in educating students for rewarding careers
through its undergraduate, graduate and doctoral degree programs in the health
and related sciences.

society university

, Ph. I am looking forward to working with the Company's team of
highly regarded clinicians , researchers, and investigators. (BLSI) is engaged in the research and
clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders.

Public Health Leaders to Convene at University of the Sciences in Philadelphia Symposium

PHILADELPHIA, A panel of the nation 's most prominent
public health leaders will convene at University of the Sciences in
Philadelphia (USP) to consider the future of public health in America. As a
follow-up to its successful, groundbreaking symposia on The Future of Medicare
and The Future of Medicaid, held in 2003 and 2004 respectively , this symposium
will address challenges facing public health in America and seek strategies
for improving the system.usip.

or at

A. The fundamental science which has been licensed from Harvard ,
Children's Hospital of Boston and other collaborating institutions is
sound.
They are:

C. Marks, MD, MPH
The Robert Wood Johnson Foundation

Kristine M.

work or

, has been appointed to the Company's
Scientific Advisory Board. He received his
doctorate in Pharmacology at Albany Medical College and his M. Martino at (215) 895-1186 or email j.

what society

Dr. A former President of
the American Society of Clinical Pharmacology and Therapeutics, Dr.

Statements in this press release regarding Boston Life Sciences'
future financial performance including statements regarding results of
operations and net loss, and any other statements about management's
future expectations , beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding
Boston Life Sciences' expectations, beliefs, intentions or strategies
regarding the future and can be identified by forward-looking words
such as "anticipate", "believe", "could", "estimate", "expect",
"intend", "may", "should", "will", and "would" or similar words.

work life

(NASDAQ: BLSI) (the "Company"), announced that Joseph R.D.C. Bianchine brings extensive experience
in medicine and clinical pharmacology to BLSI. First, he
brings broad, complimentary clinical pharmacology and product
development skills to all of our programs.
A Senior Scientific Advisor for Schwarz Pharma AG, Dr. Members
of the media will be able to ask questions during a special Q+A session
following the symposium.

or what

What it's like to live, study, or work at Johns Hopkins.

study johns

Dr. from
State University of New York (Syracuse ). "The Company's CNS product candidates
could address serious medical conditions that are presently poorly
met.

life study

D. Boston Life Sciences' actual
results could differ materially from those stated or implied in
forward-looking statements due to a number of factors, including those
factors contained in Boston Life Sciences' Annual Report on Form 10-K
filed with the Securities and Exchange Commission under the section
"Risk Factors," as well as other documents that may be filed by Boston
Life Sciences from time to time with the Securities and Exchange
Commission. to 5 p.m.

people it

, F.
Bianchine has been involved with the approval of 15 New Drug
Applications.
"Dr. For more information, visit http://www. Gebbie, DrPH, RN (moderator)
Columbia University School of Nursing

Public health today is a complex national concern. Some of the key
questions about the current and future state of public health that the
panelists will address include:

* What is the optimal relationship between the federal government and
state and local health agencies?

* How can we build and sustain public support for a strong public health
system?

* How should public health intersect with the medical care system?

* What key regulatory changes would support a stronger public health
system?

* What technologies and human resources are most needed to strengthen
public health capabilities?

The symposium is presented by the Health Policy Program at USP and
sponsored by AstraZeneca Pharmaceuticals .

college live

Bianchine,
M.C.
"I am pleased to join the Scientific Advisory Board of Boston Life
Sciences ," stated Dr.
The event brings together three nationally recognized experts, all of whom
have run major federal public health agencies, and a distinguished moderator.